You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Promoting Regular Physical Activity for Older Adults through "Wayfinding" Technology

    SBC: Azavea Inc.            Topic: N/A

    Physical vulnerability, visual impairment, mobility limitations, and cognitive disorders can make selecting a safe & accessible walking route very challenging for many older adults. Familiar online mapping & wayfinding services can be helpful, but they do not answer important questions about the built environment that older & disabled adult face on a daily basis. What are the sidewalks like alon ...

    SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  2. Identification of Patients with Clostridium Difficile Infection, Colonization and/or Reoccurrence

    SBC: AGAVE BIOSYSTEMS INC.            Topic: N/A

    Clostridium difficile infection (CDI) results in excess of 14,000 deaths and over $1 billion in excess healthcare costs annually. Early and reliable diagnosis is key for both improving treatment outcomes, and instituting precautions to prevent transmission. Antibiotic therapy can actually increase the odds of coming down with a hospital-acquired infection, especially when the cause is a bacterium ...

    SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  3. Antibody Secreting Cells (ASC) in Human Clostridium Difficile Infection, Colonization, and Reoccurrence

    SBC: MICROBPLEX, INC.            Topic: N/A

    Clostridium difficile infection (CDI) is a common nosocomial pathogen that plagues patients because of it relatively high rate of recurrence. Although diagnosis for primary CDI is very sensitive, there are not tests to predict recurrence. Recent human clinical trials show monocolonal antibodies to toxin A & B are protective for recurrent disease and some natural history studies suggest generation ...

    SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  4. XHA-A Novel Tolerance Therapeutic for Allergic Rhinitis

    SBC: VIRTICI LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to extend the development of a novel compound that can reprogram memory T lymphocytes to induce tolerance in allergic rhinitis (AR). AR is one of the most common chronic diseases in the United States (US) and is estimated to affect more than 50 million people [1,2]. As a result, the annual US economic burden of AR exceeds 12 billio ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Local Lymph Node Assay with IL-18 Endpoints

    SBC: MB RESEARCH LABORATORIES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The current industry standard for predicting contact dermal sensitization is the murine Local Lymph Node Assay (LLNA). A significant limitation of the LLNA is the frequency of false positives, as well as the occurrenceof false negatives. This limitation occurs as a result of the LLNA inability to always correctly distinguish between substances that are strongly ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Host-Targeted Mechanism of Action for Treatment of Seasonal and Pandemic Influenz

    SBC: EVRYS BIO LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Despite improvements in vaccine design, manufacture, and distribution, influenza A infection remains a significant public health concern. The February 2013 CDC Interim Adjusted Estimates of Seasonal Influenza Vaccine Effectiveness reported overall vaccine effectiveness of 56% and 67% against influenza A and B infections, respectively, with much reduced effect ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Non-invasive Diagnostic Platform Development for Celiac Disease Remission Status

    SBC: ADAPTIVE BIOTECHNOLOGIES CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): The purpose of this proposal is to adapt a technology that we have developed for monitoring residual disease in leukemia patients to monitor residual autoimmune disease in Celiac Disease patients. Celiac disease hasa significant burden on quality of life, as it is one of the most frequent autoimmune diseases, with an estimated prevalence of approximately 1% ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. A New Generation of Botulinum Toxin Vaccines

    SBC: INVENTOX INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Botulinum toxin is one of the six categories of pathogens that have been designated as Category A Select Agents by the Centers for Disease Control. The toxin, which is generally acknowledged to be the most potent biological poison known, enters the body and acts on peripheral cholinergic nerve endings to cause paralysis of transmission. In seriously poisoned pa ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. A Single Antiviral to Treat Multiple Opportunistic Infections

    SBC: EVRYS BIO LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Transplant patients are quite susceptible to opportunistic viral infection resulting from immune suppression necessary for maintenance of their graft. In the case of renal transplant, 17,604 patients in 2011, a new graft means being taken off dialysis, improving quality of life and saving U.S. healthcare nearly 1 B annually. Therefore it is essential that the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Novel bispecific T cell engaging antibodies for treatment of Lyme disease

    SBC: ABZYME THERAPEUTICS LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Lyme disease (LD) is the most commonly reported tick-borne illness in the United States. According to the recent Center for Disease Control and Prevention report, approximately 300,000 Lyme cases are diagnosed each year. If left untreated, the infection spreads to joints, the heart and the nervous system. In most cases, infections and associated symptoms are el ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government